REBIRTH Active School 2.0 . a School Based Physical Activity Program
Condition(s) studied
Investigational drug(s) / intervention(s)
Rebirth active SCHOOL 2.0 movement program: 60 Minutes of physical activity per day integrated in every school-day.
Study summary
Rebirth active SCHOOL 2.0 is a physical activity intervention program and about to be realised at 40 primary schools in Lower Saxony Germany.
Half of all schools will be assigned to the intervention program or to wait for one year before starting with the movement program. After one and two years, the follow up will take place. After completing baseline examinations (i.e. physical and cognitive functions, physical activity questionnaires) the intervention program will start for one year.
The intervention program is going to be designed with the goal of implementing physical activity of 60 minutes per day. For the main module of movement impulses, the pupils will perform a 5-minute exercise in every lesson, realised by the teachers.
Eligibility
Primary outcome measure(s)
- Change in Endurance capacity via Six-Minutes Running test — At baseline, after 1 and 2 years.
Completed meters in Six-Minutes running test: German Motor Test 6-18 (Bös, 2009): - Change in Sprint velocity via 20 meter sprint — At baseline, after 1 and 2 years.
20 meter sprint test measured in seconds: German Motor Test 6-18 (Bös, 2009). Scoring the best attempt out of two. - Change in Strength tests via 40 seconds of Push ups and sit ups — At baseline, after 1 and 2 years.
Number of repetitions in 40 seconds of Push ups and sit ups: German Motor Test 6-18 (Bös, 2009) - Change in Coordination exercise: via 60 seconds Single leg stand — At baseline, after 1 and 2 years.
Ground contacts in 60 seconds Single leg stand: German Motor Test 6-18 (Bös, 2009)
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Hanover Medical School | Hanover | Lower Saxony |
More Hannover Medical School trials in Germany
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT04942431 on ClinicalTrials.gov ↗ ← All trials in Germany